Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo

Tropical Medicine and International Health

Volumn 12, Issue 10, 2007, Pages 1164-1171

  Ndounga, Mathieu ^a   Tahar, Rachida ^b   Basco, Leonardo K ^b   Casimiro, Prisca N ^a   Malonga, David A ^c   Ntoumi, Francine ^d  

^a Centre d'Etudes sur les Ressources Végétales   (Congo)

^b Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale Cameroon   (Cameroon)

^c Centre hospitalier de Makélékélé   (Congo)

^d Medical Unity Research   (Gabon)

Author keywords

Brazzaville; Dihydrofolate reductase; Dihydropteroate synthase; Efficacy; Plasmodium falciparum; Sulfadoxine pyrimethamine; Treatment failures

Indexed keywords

ALANINE DERIVATIVE; ARGININE DERIVATIVE; CYSTEINE DERIVATIVE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; GLYCINE DERIVATIVE; ISOLEUCINE; PARACETAMOL; SERINE DERIVATIVE;

CHILD HEALTH; DISEASE TREATMENT; ENZYME; GENE; MALARIA; MUTATION; PROTOZOAN;

AGE DISTRIBUTION; ARTICLE; CONGO; CONTROLLED STUDY; DISEASE MARKER; DISEASE RESISTANCE; DRUG EFFICACY; FOLLOW UP; GENE MUTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MONOTHERAPY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; PUBLIC HEALTH SERVICE; TREATMENT FAILURE; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIMALARIALS; CHILD, PRESCHOOL; CONGO; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; FEMALE; GENETIC MARKERS; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MUTATION; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

AFRICA; BRAZZAVILLE; CENTRAL AFRICA; CONGO; SUB-SAHARAN AFRICA;

PLASMODIUM FALCIPARUM;

EID: 35448932054     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2007.01904.x     Document Type: Article

References (37)

1. Alifrangis M, Enosse S, Khalil IF et al. (2003) Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. American Journal of Tropical Medicine and Hygiene 69, 601 606.
2. Basco LK, Tahar R, Keundjian A Ringwald P (2000) Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. Journal of Infectious Diseases 182, 624 628.
3. Basco LK, Tahar R Escalante A (2004) Molecular epidemiology of malaria in Cameroon. XVIII. Polymorphisms of Plasmodium falciparum merozoite surface antigene-2 in isolates from symptomatic patients. American Journal of Tropical Medicine and Hygiene 70, 238 244.
4. Biswas S (2004) Associations of antifolate resistance in vitro and point mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum. Journal of Postgraduate Medicine 50, 17 20.
5. Brandicourt O, Carme B, Gay F, Turk P Gentilini M (1991) Widespread in vitro resistance to chloroquine of Plasmodium falciparum in the Congo, 1987. Tropical Medicine and Parasitology 42, 55 59.
6. Bwijo B, Kaneko A, Takechi M et al. (2003) High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Tropica 85, 363 373.
7. Carme B, Moudzeo H, Mbitsi A et al. (1990) La chimiorésistance médicamenteuse de Plasmodium falciparum au Congo. Bilan des enquêtes réalisées de 1985 à 1989. Bulletin de la Société de Pathologie Exotique 83, 228 241.
8. Carme B, Gay F, Chandenier J et al. (1991) Unexpected trend in chemosensitivity of Plasmodium falciparum in Brazzaville, Congo. Lancet 338, 582 583.
9. Carme B, Ndounga M, Kissila AM et al. (1998) Niveau de chloroquinorésistance inchangé (Plasmodium falciparum) chez l'enfant semi-immun depuis 1986 à Brazzaville. Bulletin de la Société de Pathologie Exotique 91, 164 166.
10. Chandenier J, Ndounga M, Carme B et al. (1995) Chimiosensibilité in vivo et in vitro de Plasmodium falciparum à Brazzaville (Congo). Cahiers d'études et de recherches francophones/Santé 5, 25 29.
11. Cohuet S, Bonnet M, Van Herp M et al. (2006) Molecular markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo. American Journal of Tropical Medicine and Hygiene 75, 152 154.
12. Coulibaly SO, Nezien D, Traore S, Kone B Magnussen P (2006) Therapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso. Malaria Journal 5, 49.
13. Curtis J, Duraisingh MT Warhurst DC (1998) In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. Journal of Infectious Diseases 177, 1429 1433.
14. Kazadi WM, Vong S, Makina BN et al. (2003) Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in the Democratic Republic of Congo. Tropical Medicine and International Health 8, 868 875.
15. Kublin JG, Witzig RS, Shankar AH et al. (1998) Molecular assays for surveillance of antifolate-resistant malaria. Lancet 351, 1629 1630.
16. Kublin JG, Dzinjalamala FK, Kamwendo DD et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Journal of Infectious Diseases 185, 380 388.
17. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ Dorsey G (2003) Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. American Journal of Tropical Medicine and Hygiene 69, 247 252.
18. Lukuka KA, Fumie OS, Mulumbu MR, Lokombe BJ Muyembe TJ (2006) Prévalence du paludisme à l'accouchement dans quatre maternités de la ville de Kinshasa, République Démocratique du Congo. Bulletin de la Société de Pathologie Exotique 99, 200 201.
19. Menard D, Djalle D, Yapou F, Manirakiza A Tamarlin A (2006) Frequency distribution of antimalarial drug-resistant alleles among isolates of Plasmodium falciparum in Bangui, Central African Republic. American Journal of Tropical Medicine and Hygiene 74, 205 210.
20. Mendez F, Munoz A, Carrasquilla G et al. (2002) Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. American Journal of Epidemiology 156, 230 238.
21. Mockenhaupt FP, Teun Bousema J, Eggelte TA et al. (2005) Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine- pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Tropical Medicine and International Health 10, 901 908.
22. Nsimba B, Malonga DA, Mouata AM et al. (2004) Efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo. American Journal of Tropical Medicine and Hygiene 70, 133 138.
23. Nsimba B, Jafari-Guemouri S, Malonga DA et al. (2005) Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. Tropical Medicine and International Health 10, 1030 1037.
24. Plowe CV, Cortese JF, Djimde A et al. (1997) Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. Journal of Infectious Diseases 176, 1590 1596.
25. Sokhna CS, Trape JF Robert V (2001) Gametocytaemia in Senegalese children with uncomplicated falciparum malaria treated with chloroquine, amodiaquine or sulfadoxine + pyrimethamine. Parasite 8, 243 250.
26. Sowunmi A, Fateye BA, Adedeji AA et al. (2005) Effects of antifolates-co-trimoxazole and pyrimethamine-sulfadoxine on gametocytes in children with acute, symptomatic, uncomplicated, Plasmodium falciparum malaria. Memorias do Instituto Oswaldo Cruz 100, 451 455.
27. Tahar R Basco LK (2006) Molecular epidemiology of malaria in Cameroon. XXIII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles. American Journal of Tropical Medicine and Hygiene 75, 396 401.
28. Talisuna AO, Nalunkuma-Kazibwe A, Langi P et al. (2004) Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infection, Genetics and Evolution 4, 321 327.
29. Tjitra E, Suprianto S Anstey NM (2002) Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance. Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 434 437.
30. Trape JF (1987) Malaria and urbanization in central Africa: the example of Brazzaville. Part II. Results of entomological surveys and epidemiological analysis. Transactions of the Royal Society of Tropical Medicine and Hygiene 81 (Suppl. 2 10 18.
31. Triglia T, Menting JG, Wilson C Cowman AF (1997) Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proceedings of the National Academy of Sciences, U S A 94, 13944 13949.
32. Wang P, Lee CS Bayoumi R et al. (1997) Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Molecular and Biochemical Parasitology 89, 161 177.
33. White NJ (2005) Intermittent presumptive treatment for malaria. PloS Medicine 2, 28 33.
34. World Heath Organization (1973) Chemotherapy of Malaria and Resistance to Antimalarials. Report of a WHO Scientific Group. Technical Report Series No. 529. World Health Organization, Geneva.
35. World Heath Organization (1996) Assessment of Therapeutic Efficacy for Uncomplicated falciparum Malaria in Areas With Intense Transmission. World Heath Organization, Geneva. WHO/MAL/96.1077.
36. World Heath Organization (2003) Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated falciparum Malaria. World Heath Organization, Geneva. WHO/HTM/RBM/2003.50.
37. World Heath Organization (2006) Guidelines for the Treatment of Malaria. World Heath Organization, Geneva. WHO/HTM/2006.11108.